These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27668396)

  • 21. Feasibility and benefit of concurrent chemoradiotherapy for elderly patients with uterine cervical cancer.
    Nosaka K; Shibata K; Utsumi F; Yoshida K; Niimi K; Sekiya R; Suzuki S; Kajiyama H; Kikkawa F
    Tumori; 2016 Dec; 102(6):600-605. PubMed ID: 27443893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement.
    Mariani A; Webb MJ; Keeney GL; Calori G; Podratz KC
    Gynecol Oncol; 2001 Oct; 83(1):72-80. PubMed ID: 11585416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postoperative concurrent chemoradiotherapy for the high-risk uterine cervical cancer.
    Takeshita S; Kita T; Motoike Y; Umezawa K; Sugisaki S; Matsumoto S; Matsumoto Y; Ryo E; Ayabe T
    J Obstet Gynaecol Res; 2010 Oct; 36(5):1009-14. PubMed ID: 20722988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a multicenter retrospective Korean study (KGOG-1005).
    Ryu HS; Kang SB; Kim KT; Chang KH; Kim JW; Kim JH
    Int J Gynecol Cancer; 2007; 17(1):132-6. PubMed ID: 17291243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors.
    Mabuchi S; Morishige K; Isohashi F; Yoshioka Y; Takeda T; Yamamoto T; Yoshino K; Enomoto T; Inoue T; Kimura T
    Gynecol Oncol; 2009 Dec; 115(3):482-7. PubMed ID: 19783286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Features of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review.
    Nagao S; Miwa M; Maeda N; Kogiku A; Yamamoto K; Morimoto A; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Sakuma T; Fujiwara K
    Int J Gynecol Cancer; 2015 Sep; 25(7):1300-5. PubMed ID: 26166556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients with cervical cancer who underwent radical hysterectomy and systematic lymphadenectomy.
    Hosaka M; Watari H; Kato T; Odagiri T; Konno Y; Endo D; Mitamura T; Kikawa S; Suzuki Y; Sakuragi N
    J Surg Oncol; 2012 May; 105(6):612-6. PubMed ID: 22065519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of international Federation of gynecology and obstetrics stage IIb cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study.
    Guo L; Liu X; Wang L; Sun H; Huang K; Li X; Tang F; Li S; Yuan X; Wang C
    Int J Gynecol Cancer; 2015 Jun; 25(5):910-8. PubMed ID: 25867278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lower urinary tract dysfunction and quality of life in cervical cancer survivors after concurrent chemoradiation versus radical hysterectomy.
    Katepratoom C; Manchana T; Amornwichet N
    Int Urogynecol J; 2014 Jan; 25(1):91-6. PubMed ID: 23818129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy.
    Kim SW; Chun M; Ryu HS; Chang SJ; Kong TW; Oh YT; Kang SH
    BMC Cancer; 2017 Apr; 17(1):297. PubMed ID: 28454573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I Dose-Escalation Study of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in Stages IB2 and IIA2 Cervical Cancer.
    Chou HH; Huang HJ; Lin H; Yang LY; Hsueh S; Liu FY; Liou YL; Liou JD; Chen MY; Chao A; Lin G; Chang TC; Lai CH
    Am J Clin Oncol; 2017 Jun; 40(3):241-249. PubMed ID: 25350466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of occult invasive cervical cancer found after simple hysterectomy.
    Park JY; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
    Ann Oncol; 2010 May; 21(5):994-1000. PubMed ID: 19858083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
    Yin YJ; Li HQ; Sheng XG; Du XL; Wang C; Lu CH; Pan CX
    Int J Gynecol Cancer; 2015 Jul; 25(6):1058-65. PubMed ID: 25647254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radical hysterectomy after chemoradiation in FIGO stage III cervical cancer patients versus chemoradiation and brachytherapy: Complications and 3-years survival.
    Fanfani F; Vizza E; Landoni F; de Iaco P; Ferrandina G; Corrado G; Gallotta V; Gambacorta MA; Fagotti A; Monterossi G; Perrone AM; Lazzari R; Colangione SP; Scambia G
    Eur J Surg Oncol; 2016 Oct; 42(10):1519-25. PubMed ID: 27241922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors.
    Kim YB; Cho JH; Keum KC; Lee CG; Seong J; Suh CO; Kim GE
    Gynecol Oncol; 2007 Jan; 104(1):58-63. PubMed ID: 16919718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma.
    Mabuchi S; Okazawa M; Matsuo K; Kawano M; Suzuki O; Miyatake T; Enomoto T; Kamiura S; Ogawa K; Kimura T
    Gynecol Oncol; 2012 Oct; 127(1):114-20. PubMed ID: 22728518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Definitive chemoradiotherapy for advanced cervical cancer: should it be different in the elderly?
    Caires IQ; Souza KT; Negrão MV; de Oliveira JA; Barroso-Sousa R; de Lima RC; Hoff PM; Diz Mdel P
    Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():86-9. PubMed ID: 26182837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between location of transposed ovary and function in cervical cancer patients who underwent radical hysterectomy.
    Yoon A; Lee YY; Park W; Huh SJ; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
    Int J Gynecol Cancer; 2015 May; 25(4):688-93. PubMed ID: 25675036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
    Lee HN; Lee KH; Lee DW; Lee YS; Park EK; Park JS
    Int J Gynecol Cancer; 2011 Jan; 21(1):128-36. PubMed ID: 21330837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daily low-dose cisplatin-based concurrent chemoradiotherapy in patients with uterine cervical cancer with emphasis on elderly patients: a phase 2 trial.
    Mitsuhashi A; Uno T; Usui H; Nishikimi K; Yamamoto N; Watanabe M; Tate S; Hirashiki K; Kato K; Yamazawa K; Shozu M
    Int J Gynecol Cancer; 2013 Oct; 23(8):1453-8. PubMed ID: 23266648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.